Combination treatment for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called nelmastobart combined with two standard chemotherapy drugs (TAS-102 and bevacizumab) for people with colorectal cancer that has spread or returned and hasn't responded to earlier treatments. The goal is to see if this combination can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have colorectal cancer that has spread or come back and has not improved with previous treatments (including oxaliplatin and irinotecan).
- You have at least one tumor that can be measured on a scan.
- You are able to take care of yourself (ECOG score 0 or 1).
- Your blood and organ functions are adequate (specific lab test requirements).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug, nelmastobart, combined with two standard chemotherapy drugs (trifluridine/tipiracil and bevacizumab) for people with advanced colorectal cancer that hasn't responded to other treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a combination of two drugs (bevacizumab and adebrelimab) for people with a specific type of advanced colorectal cancer that has not responded to standard treatments. It aims to see if this combination can help control the cancer and improve outcomes.
This trial tests a combination of focused radiation (SBRT), chemotherapy (CAPEOX), and two targeted drugs (bevacizumab and an immunotherapy) for colorectal cancer that has spread and can't be removed by surgery. The goal is to see if this combination can shrink tumors and help you live longer.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
This trial tests a new drug, nelmastobart, combined with the chemotherapy docetaxel, for people with advanced non-small cell lung cancer that has a high level of a protein called BTN1A1. It is for patients who have already tried other treatments and are looking for a new option.
Hear when a new Colonrectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.